CK Burris, NQ Richards, CL Jr Cowan, Erlotinib Associated Trichomegaly in a Patient with Chronic Latanoprost Use, Journal of Hematology and Oncology Research, Volume 1, Issue 4, 2015, Pages 31-35, ISSN 2372-6601, https://doi.org/10.14302/issn.2372-6601.jhor-15-667.
(https://oapgroup.org/jhor/article/189)
Abstract: Trichomegaly is a known adverse effect with the epidermal growth factor receptor inhibitor (EGFRI) and prostaglandin analogue drug classes. We present a chronic Latanoprost user who developed symptomatic trichomegaly subsequent to initiating an EGFRI medication and believe this case offers evidence that the two classes of medications may cause a similar eyelash manifestation through different mechanisms.
Keywords: trichomegaly; oncology